Technologies, Trends, And Challenges For CGT In 2023 (And Beyond)

As advancements in technology, foundational science, and workflows continue to open up potential within the cell and gene therapy space, issues such as pricing, reimbursement, capacity, supply chains, and other broad variables will continue to impact the landscape in the coming years. Between the innovative platform technologies that have begun to automate parts of manufacturing and increasing investigation into more widespread disease states these treatments can address, the cell and gene therapy space is poised for paradigmatic shifts. Some key innovations the industry is likely to see in the coming years will center on promising technologies and modalities, including:

• Viral and non-viral vectors
• Ex vivo and in vivo gene therapies
• Induced pluripotent stem cells (IPSCs)
• Genomic editing
• Autologous and allogeneic stem cell therapies

In addition, supply chain constraints, manufacturing considerations such as when to outsource or insource, and resourcing considerations will continue to impact the sector in ever-evolving ways. The coming year is likely to yield a number of key advancements for the space, owing to the continued collaboration of players across a wide range of scientific and medical disciplines and teams.